Literature DB >> 3302173

Hyperacute rejection in a discordant (pig to baboon) cardiac xenograft model.

G Lexer, D K Cooper, A G Rose, W N Wicomb, J Rees, M Keraan, E Du Toit.   

Abstract

Eight freshly excised pig hearts were hemoperfused by baboons in vivo. Cardiac function ceased in six hearts after a mean period of 90 minutes of perfusion (range 30 to 190 minutes). Two hearts continued functioning for the 4-hour study period. On microscopic examination, seven hearts, including one that continued beating, showed histopathologic features of hyperacute rejection. IgG, IgM, and C3 were strongly present on the myocardium in all cases. Hemoperfusion was associated with significant increases in heart mass (p less than 0.002) and circulating polymorphonuclear leukocytes (p less than 0.03) and reductions in coronary blood flow (p less than 0.0001), circulating lymphocytes (p less than 0.03), and C4 (p less than 0.03). Preformed circulating anti-pig antibodies disappeared in all but one baboon. Hyperacute rejection in this discordant xenograft model that used a nonhuman primate as "recipient" differs in few aspects from that seen in other experimental models. Possible methods of prolonging xenograft survival are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3302173

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  22 in total

1.  Immunofluorescent localization of pig complement component 3, regardless of the presence or absence of detectable immunoglobulins, in hyperacutely rejected heart xenografts.

Authors:  M W Wang; P S Johnston; L J Wright; S M Lim; D J White
Journal:  Histochem J       Date:  1992-02

Review 2.  In Search of the Ideal Valve: Optimizing Genetic Modifications to Prevent Bioprosthetic Degeneration.

Authors:  Benjamin Smood; Hidetaka Hara; David C Cleveland; David K C Cooper
Journal:  Ann Thorac Surg       Date:  2019-03-02       Impact factor: 4.330

Review 3.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

4.  Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs.

Authors:  Whayoung Lee; Hidetaka Hara; Mohamed B Ezzelarab; Hayato Iwase; Rita Bottino; Cassandra Long; Jagdeece Ramsoondar; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2016-03-14       Impact factor: 3.907

Review 5.  Overcoming Coagulation Dysregulation in Pig Solid Organ Transplantation in Nonhuman Primates: Recent Progress.

Authors:  Liaoran Wang; David K C Cooper; Lars Burdorf; Yi Wang; Hayato Iwase
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 6.  New concepts of immune modulation in xenotransplantation.

Authors:  Vikas Satyananda; Hidetaka Hara; Mohamed B Ezzelarab; Carol Phelps; David Ayares; David K C Cooper
Journal:  Transplantation       Date:  2013-12-15       Impact factor: 4.939

Review 7.  Immunobiological barriers to xenotransplantation.

Authors:  David K C Cooper; Burcin Ekser; A Joseph Tector
Journal:  Int J Surg       Date:  2015-07-06       Impact factor: 6.071

Review 8.  Immunobiology of liver xenotransplantation.

Authors:  Burcin Ekser; Christopher Burlak; Joshua P Waldman; Andrew J Lutz; Leela L Paris; Massimiliano Veroux; Simon C Robson; Michael A Rees; David Ayares; Bruno Gridelli; A Joseph Tector; David Kc Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

Review 9.  Progress in pig-to-non-human primate transplantation models (1998-2013): a comprehensive review of the literature.

Authors:  David K C Cooper; Vikas Satyananda; Burcin Ekser; Dirk J van der Windt; Hidetaka Hara; Mohamed B Ezzelarab; Henk-Jan Schuurman
Journal:  Xenotransplantation       Date:  2014-09-01       Impact factor: 3.907

Review 10.  Current status of pig kidney xenotransplantation.

Authors:  Hayato Iwase; Takaaki Kobayashi
Journal:  Int J Surg       Date:  2015-08-22       Impact factor: 6.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.